Modulation of camptothecin analogs in the treatment of cancer: A review

Anti-Cancer Drugs

Volumn 12, Issue 2, 2001, Pages 89-105

  Kehrer, D F S ^a   Soepenberg, O ^a   Loos, W J ^a   Verweij, J ^a   Sparreboom, A ^a  

^a ERASMUS MC CANCER INSTITUTE   (Netherlands)

Author keywords

Camptothecin analogs; Modulation; Pharmacokinetics; Topoisomerase I

Indexed keywords

9 AMINOCAMPTOTHECIN; CAMPTOTHECIN DERIVATIVE; DIFLOMOTECAN; DRUG VEHICLE; EXATECAN; IRINOTECAN; LURTOTECAN; RUBITECAN; SILATECAN DERIVATIVE; TOPOTECAN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; CLINICAL TRIAL; DRUG FORMULATION; DRUG SOLUBILITY; HUMAN; MALIGNANT NEOPLASTIC DISEASE; PHARMACODYNAMICS; PRIORITY JOURNAL; REVIEW; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; DNA TOPOISOMERASES, TYPE I; DRUG DELIVERY SYSTEMS; DRUG SYNERGISM; ENZYME INHIBITORS; HUMANS; NEOPLASMS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0035098297     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200102000-00002     Document Type: Review

References (179)

1. Camptothecin and taxol: Discovery to clinic
2. Phase I clinical trial of weekly and daily treatment with camptothecin (NSC-100880): Correlation with preclinical studies
3. Toxicity of camptothecin (NSC-100880)
4. Phase II study of camptothecin (NSC-100880) in the treatment of advanced gastrointestinal cancer
5. Topoisomerase I inhibitors: Topotecan and irenotecan
6. Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin
7. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I
8. Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin
9. DNA topoisomerase I - Targeted chemotherapy of human colon cancer in xenografts
10. P-glycoprotein expression and DNA topoisomerase I and II activity in benign tumors of the ovary and in malignant tumors of the ovary, before and after platinum/cyclophosphamfide chemotherapy
11. Camptothecins: From bench research to hospital wards
12. Clinical activity and benefit of irinotecan (CPT-11) in patients with colorectal cancer truly resistant to 5-fluorouracil (5-FU)
13. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer
14. Activity of CPT-11 (irinotecan hydrochloride), a topoisomerase I inhibitor, against human tumor colony-forming units
15. Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-lO-(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin against pediatric and adult central nervous system tumor xenografts
16. Comparison of topoisomerase I inhibition, DNA damage, and cytotoxicity of camptothecin derivatives presently in clinical trials
17. Characterization of CPT-11 hydrolysis by human liver carboxylesterase isoforms hCE-1 and hCE-2
18. Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform IA1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes
19. Activity of topotecan, a new topoisomerase I inhibitor, against human tumor colony-forming units in vitro
20. Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors
21. Antitumor effect of liposome-incorporated camptothecin in human malignant xenografts
22. Complete growth inhibition of human cancer xenografts in nude mice by treatment with 20-(S)-camptothecin
23. Complete inhibition of growth followed by death of human malignant melanoma cells in vitro and regression of human melanoma xenografts in immunodeficient mice induced by camptothecins
24. Phase I and pharmacologic study of oral (PEG-1000) 9-aminocamptothecin in adult patients with solid tumors
25. Phase I trial of low-dose continuous topotecan infusion in patients with cancer: An active and well-tolerated regimen
26. Phase I and pharmacokinetic study of irinotecan administered as a low-dose, continuous intravenous infusion over 14 days in patients with malignant solid tumors
27. Continuous infusion of low-dose topotecan: Pharmacokinetics and pharmacodynamics during a phase II study in patients with small cell lung cancer
28. Phase II trial of topotecan administered as a 21-day continuous infusion in previously untreated patients with stage IIIB and IV non-small-cell lung cancer
29. Phase II and pharmacologic study of topotecan administered as a 21-day continuous infusion to patients with colorectal cancer
30. Structure-activity relation in camptothecin antitumor drugs: Why a detailed molecular characterisation of their lactone and carboxylate forms by Raman and SERS spectroscopies?
31. Clinical applications of the camptothecins
32. Synthesis and antitumor activity of ring A- and F-modified hexacyclic camptothecin analogues
33. Synthesis and antitumor activity of novel water soluble derivatives of camptothecin as specific inhibitors of topoisomerase I
34. Synthesis, topoisomerase I inhibitory activity, and in vivo evaluation of 11-azacamptothecin analogs
35. 7- and 10-substituted camptothecins: Dependence of topoisomerase I-DNA cleavable complex formation and stability on the 7- and lO-substituents
36. Modulation in kinetics of lactone ring hydrolysis of camptothecins upon interaction with topoisomerase I cleavage sites on DNA
37. The important role of albumin in determining the relative human blood stabilities of the camptothecin anticancer drugs
38. Role of erythrocytes and serum proteins in the kinetic profile of total 9-amino-20(S)-camptothecin in humans
39. Pharmacokinetics of prolonged-release CPT-11-loaded microspheres in rats
40. The acidic microclimate in poly(lactide-co-glycolide) microspheres stabilizes camptothecins
41. Stabilization of 10-hydroxycamptothecin in poly(lactide-co-glycolide) microsphere delivery vehicles
42. Poly(D,L-lactic-coglycolic acid) microspheres for sustained delivery and stabilization of camptothecin
43. The acidic microclimate in poly(lactide-co-glycolide) microspheres stabilizes camptothecins
44. Liposomal encapsulation increases the activity of the topoisomerase I inhibitor topotecan
45. Stabilization of topotecan in low pH liposomes composed of distearoylphosphatidylcholine
46. Effect of liposomalization on the antitumor activity, side-effects and tissue distribution of CPT-11
47. Effective irinotecan (CPT-11)-containing liposomes: Intraliposomal conversion to the active metabolite SN-38
48. Liposomal encapsulation of topotecan enhances anticancer efficacy in murine and human xenograft models
49. Antitumor efficacy, pharmacokinetics, and biodistribution of NX 211: A low-clearance liposomal formulation of lurtotecan
50. Encapsulation of the topoisomerase I inhibitor GL147211C in pegylated (STEALTH) liposomes: Pharmacokinetics and antitumor activity in HT29 colon tumor xenografts
51. Liposomal lurtotecan (NX211): Determination of total drug levels in human plasma and urine by reversed-phase high-perfomance liquid chromatography
52. Body distribution in mice of intravenously injected camptothecin solid lipid nanoparticles and targeting effect on brain
53. Equilibrium kinetics of the new experimental anti-tumour compound SKF 104864-A in aqueous solution
54. 9-Aminocamptothecin by 72-hour continuous intravenous infusion is inactive in the treatment of patients with 5-fluorouracil-refractory colorectal carcinoma
55. A phase I and pharmacokinetic study of a new camptothecin derivative, 9-aminocamptothecin
56. Phase I and pharmacologic study of 9-aminocamptothecin given by 72-hour infusion in adult cancer patients
57. Pharmacodynamics and pharmacokinetics of a 72-hour infusion of 9-aminocamptothecin in adult cancer patients
58. Phase I and pharmacologic study of 9-aminocamptothecin colloidal dispersion formulation given as a 24-hour continuous infusion weekly times four every 5 weeks
59. A phase II study of 9-aminocamptothecin in patients with refractory breast cancer
60. Phase I and pharmacologic study of 9-aminocamptothecin colloidal dispersion formulation in patients with refractory or relapsed acute leukemia
61. Phase I and pharmacokinetic study of a daily times 5 short intravenous infusion schedule of 9-aminocamptothecin in a colloidal dispersion formulation in patients with advanced solid tumors
62. Phase II trial of 9-aminocamptothecin administered as a 72-hour continuous infusion in metastatic colorectal carcinoma
63. Phase II trial of 9-aminocamptothecin (NSC 603071) administered as a 120-hr continuous infusion weekly for three weeks in metastatic colorectal carcinoma
64. A phase II study of 9-aminocamptothecin in advanced non-small-cell lung cancer
65. Homocamptothecins: Synthesis and antitumor activity of novel E-ring- modified camptothecin analogues
66. Topoisomerase I-mediated antiproliferative activity of enantiomerically pure fluorinated homocamptothecins
67. Homocamptothecin, an E-ring modified camptothecin with enhanced lactone stability, retains topoisomerase I-targeted activity and antitumor properties
68. Homocamptothecin, an E-ring-modified camptothecin, exerts more potent antiproliferative activity than other topoisomerase I inhibitors in human colon cancers obtained from surgery and maintained in vitro under histotypical culture conditions
69. Homocamptothecin, an E-ring-modified camptothecin analogue, generates new topoisomerase I-mediated DNA breaks
70. Homocamptothecin, an E-ring modified camptothecin with enhanced lactone stability, retains topoisomerase I-targeted activity and antitumor properties
71. The other camptothecins: Recent advances with camptothecin analogues other than irinotecan and topotecan
72. BN 80927: A novel homocamptothecin with inhibitory activities on both topoisomerase I and topoisomerase II
73. Potent topoisomerase I inhibition by novel silatecans eliminates glioma proliferation in vitro and in vivo
74. In vivo antitumor activity of two new seven-substituted water-soluble camptothecin analogues
75. Phase I and pharmacological study of the new topoisomerase I inhibitor GI147211, using a daily x5 intravenous administration
76. Phase I and pharmacokinetic study of GI147211, a water-soluble camptothecin analogue, administered for five consecutive days every three weeks
77. A phase I clinical and pharmacokinetic study of the new topoisomerase inhibitor GI147211 given as a 72-h continuous infusion
78. The bioavailability of oral GI147211 (GG211), a new topoisomerase I inhibitor
79. A new water-soluble camptothecin derivative, DX-8951f, exhibits potent antitumor activity against human tumors in vitro and in vivo
80. Comparison of DX-8951f and topotecan effects on tumor colony formation from freshly explanted adult and pediatric human tumor cells
81. The topoisomerase I inhibitor DX-8951f is active in a severe combined immunodeficient mouse model of human acute myelogenous leukemia
82. DX-8951 f, a hexacyclic camptothecin analog, on a daily-times-five schedule: A phase I and pharmacokinetic study in patients with advanced solid malignancies
83. Phase I and pharmacokinetic (PK) study of DX-8951f, a novel camptothecin analog, given as a 30 minute infusion daily for 5 days
84. Final results of a phase I and pharmacokinetic study of DX-8951f in patients with advanced tumors
85. Phase I study and pharmacology of DX-8951f, a new camptothecin derivative administered over 30 minutes every 3 weeks
86. A phase I and pharmacokinetic study of the camptothecin (CPT) analog DX-8951f (exetacan mesylate): Escalating infusion duration and dose
87. Phase II study of exatecan mesylate (DX-8951f) in advanced NSCLC
88. A phase II study of exatecan mesylate (DX-8951f, DX) in advanced pancreatic cancer
89. Phase II study of intravenous DX-8951f in patients (Pts) with advanced ovarian, tubal, or peritoneal cancer refractory to platinum, taxane, and topotecan
90. A phase II study of intravenous exatecan mesylate (Dx-8951f, Dx) administered daily for five days every three weeks to patients with advanced or metastatic adenocarcinoma of the colon or rectum
91. Enhanced cytogenetic and antitumor effects by 9-nitrocamptothecin and antineoplastics
92. Cytotoxic efficacy of 9-nitrocamptothecin in the treatment of human malignant melanoma cells in vitro
93. Pharmacokinetics of the in vivo and in vitro conversion of 9-nitro-20(S)-camptothecin to 9-amino-20(S)-camptothecin in humans, dogs, and mice
94. Oral topoisomerase 1 inhibitors in adult patients: Present and future
95. A study of 9-nitrocamptothecin (RFS-2000) in patients with advanced pancreatic cancer
96. A phase II clinical and pharmacological study of oral 9-nitrocamptothecin in patients with refractory epithelial ovarian, tubal or peritoneal cancer
97. Camptothecin delivery systems: The utility of amino acid spacers for the conjugation of camptothecin with polyethylene glycol to create prodrugs
98. Camptothecin delivery systems: The antitumor activity of a camptothecin- 20-O-polyethylene glycol ester transport form
99. Tumoritropic and lymphotropic principles of macromolecular drugs
100. Complete regression of xenografted human carcinomas by camptothecin analogue-carboxymethyl dextran conjugate (T-0128)
101. Polymer-bound camptothecin: Initial biodistribution and antitumour activity studies
102. A phase I study of PEG-camptothecin (PEG-CPT) in patients with advanced solid tumors: A novel formulation for an insoluble but active agent
103. Phase I pharmacokinetic (PK) study of MAG-CPT (PNU 166148), a polymeric derivative of camptothecin (CPT)
104. Phase I and pharmacokinetics study of topotecan, a new topoisomerase I inhibitor
105. A phase I and pharmacological study of topotecan infused over 30 minutes for five days in patients with refractory acute leukemia
106. Phase I/pharmacokinetic study of topotecan by 24-hour continuous infusion weekly
107. Phase I clinical and pharmacokinetic study of topotecan administered by a 24-hour continuous infusion
108. Activity and pharmacodynamics of 21-day topotecan infusion in patients with ovarian cancer previously treated with platinum-based chemotherapy
109. Randomized phase II study of two schedules of topotecan in previously treated patients with ovarian cancer: A National Cancer Institute of Canada Clinical Trials Group study
110. Continuous infusional topotecan in advanced breast and non-small-cell lung cancer: No evidence of increased efficacy
111. Topote
112. Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients
113. Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer
114. Phase I and pharmacokinetic study of the camptothecin derivative irinotecan, administered on a weekly schedule in cancer patients
115. CPT-11: Clinical experience in phase I studies
116. Phase I and pharmacologic study of irinotecan administered as a 96-hour infusion weekly to adult cancer patients
117. Phase I study and pharmacokinetics of CPT-11 with 5-day continuous infusion
118. Bioavailability and pharmacokinetics of oral topotecan: A new topoisomerase I inhibitor
119. Oral topotecan: Bioavailablity and effect of food co-administration
120. Interpatient variability in bioavailability of the intravenous formulation of topotecan given orally to children with recurrent solid tumors
121. Pharmacokinetics and bioavailability of oral 9-aminocamptothecin capsules in adult patients with solid tumors
122. Phase I clinical and pharmacokinetic study of oral 9-aminocamptothecin (NSC-603071)
123. Disposition of irinotecan and SN-38 following oral and intravenous irinotecan dosing in mice
124. Five days of oral topotecan (Hycamtin), a phase I and pharmacological study in adult patients with solid tumours
125. Oral topotecan given once or twice daily for ten days: A phase I pharmacology study in adult patients with solid tumors
126. Phase I and pharmacologic study of oral topotecan administered twice daily for 21 days to adult patients with solid tumors
127. A comparison of clinical pharmacodynamics of different administration schedules of oral topotecan (Hycamtin)
128. A multicentre randomised phase II study of oral topotecan versuis IV topotecan for second line therapy i sensitive patients with small cell lung cancer
129. A multicentre, randomised, phase III study of topotecan (T) administered intravenously or orally for advanced epithelial ovarian carcinoma
130. CPT-11 converting carboxylesterase and topoisomerase activities in tumour and normal colon and liver tissues
131. Efficacy of oral irinotecan against neuroblastoma xenografts
132. Altered irinotecan and SN-38 disposition after intravenous and oral administration of irinotecan in mice bearing human neuroblastoma xenografts
133. Phase I and pharmacokinetic trial of oral irinotecan administered daily for 5 days every 3 weeks in patients with solid tumors
134. Hepatic artery chemoembolization (CE) with irinotecan (I) for primary and metstatic liver cancer; Preliminary results
135. Pharmacokinetic and pharmacodynamics of CPT-11 during 5-day hepatic arterial (HAI) and intravenous (i.v.) infusion
136. Anticancer effect of 9-nitrocamptothecin liposome aerosol on human cancer xenografts in nude mice
137. 9-Nitrocamptothecin liposome aerosol treatment of melanoma and osteosarcoma lung metastases in mice
138. Distribution of camptothecin after delivery as a liposome aerosol or following intramuscular injection in mice
139. Anti-cancer activity of 9-nitrocamptothecin liposome aerosol in mice
140. Phase I and pharmacokinetic study of intraperitoneal topotecan
141. Pharmacokinetic optimisation of cancer chemotherapy. Effect on outcomes
142. Topotecan and the treatment of recurrent ovarian cancer: Is there a role for granulocyte colony-stimulating factor?
143. Phase I clinical and pharmacology study of topotecan given daily for 5 consecutive days to patients with advanced solid tumors, with attempt at dose intensification using recombinant granulocyte colony-stimulating factor
144. High-dose topotecan with granulocyte colony stimulating factor in fluoropyrimidine-refractory colorectal cancer: A phase II and pharmacodynamic study
145. Phase I and pharmacologic study of high doses of the topoisomerase I inhibitor topotecan with granulocyte colony-stimulating factor in patients with solid tumors
146. Phase I clinical and plasma and cellular pharmacological study of topotecan without and with granulocyte colony-stimulating factor
147. Phase II and dose-escalation with or without granulocyte colony-stimulating factor study of 9-aminocamptothecin in relapsed and refractory lymphomas
148. Phase I and pharmacologic study of irinotecan and etoposide with recombinant human granulocyte colony-stimulating factor support for advanced lung cancer
149. Phase I/II study of cisplatin, ifosfamide and irinotecan with rhG-CSF support in patients with stage IIIB and IV non-small-cell lung cancer
150. A phase I clinical and pharmacological study of oral 9-nitrocamptothecin, a novel water-insoluble topoisomerase I inhibitor
151. Characterisation and clinical management of CPT-11 (irinotecan)-induced adverse events: The European perspective
152. CPT-11-induced cholinergic effects in cancer patients
153. The mechanism for the inhibition of acetylcholinesterases by irinotecan (CPT-11)
154. Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy
155. Inhibition of intestinal microflora beta-glucuronidase modifies the distribution of the active metabolite of the antitumor agent, irinotecan hydrochloride (CPT-11) in rats
156. Diffuse mucosal damage in the large intestine associated with Irinotecan (CPT-11)
157. Irinotecan (CPT-11) high-dose escalation using intensive high-dose loperamide to control diarrhea
158. Randomized comparison of prophylactic antidiarrheal treatment versus no prophylactic antidiarrheal treatment in patients receiving CPT-11 (irinotecan) for advanced 5-FU-resistant colorectal cancer: An open-label multicenter phase II study
159. Glutamine for irinotecan diarrhea
160. Prevention of intestinal toxic effects and intensification of irinotecan's therapeutic efficacy against murine colon cancer liver metastases by oral administration of the lipopeptide JBT 3002
161. Interleukin 15 offers selective protection from irinotecan-induced intestinal toxicity in a preclinical animal model
162. Effect of thalidomide on gastrointestinal toxic effects of irinotecan
163. Metabolic fate of irinotecan in humans: Correlation of glucuronidation with diarrhea
164. Involvement of beta-glucuronidase in intestinal microflora in the intestinal toxicity of the antitumor camptothecin derivative irinotecan hydrochloride (CPT-11) in rats
165. Protective effects of kampo medicines and baicalin against intestinal toxicity of a new anticancer camptothecin derivative, irinotecan hydrochloride (CPT-11), in rats
166. Kampo medicines for the prevention of irinotecan-induced diarrhea in advanced non-small cell lung cancer
167. pH-dependent uptake of irinotecan and its active metabolite, SN-38, by intestinal cells
168. Intestinal MDR transport proteins and P-450 enzymes as barriers to oral drug delivery
169. Pharmacodynamic-pharmacokinetic relationships and therapeutic drug monitoring
170. Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line
171. Breast cancer resistance protein is localized at the plasma membrane in mitoxant
172. Identification of a new metabolite of CPT-11 (irinotecan): Pharmacological properties and activation to SN-38
173. Metabolism of irinotecan (CPT-11) by human hepatic microsomes: Participation of cytochrome P-450 3A and drug interactions
174. Metabolism of irinotecan (CPT-11) by CYP3A4 and CYP3A5 in humans
175. Pharmacokinetic modulation of irinotecan and metabolites by cyclosporin A
176. Modulation of glucuronidation of SN-38, the active metabolite of irinotecan, by valproic acid and phenobarbital
177. Clinical pharmacology of camptothecins
178. Overexpression of a rabbit liver carboxylesterase sensitizes human tumor cells to CPT-11
179. Comparison of activation of CPT-11 by rabbit and human carboxylesterases for use in enzyme/prodrug therapy